{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:09:53Z","timestamp":1791166193971,"version":"4.1.0"},"reference-count":12,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T00:00:00Z","timestamp":1468022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:p>Abiraterone is an inhibitor of androgen biosynthesis indicated for the treatment of metastatic castration-resistant prostate cancer. Common side effects include diarrhea, edema, hypokalemia, hypertension, and liver function test abnormalities. We report a case of rhabdomyolysis developing in association with the use of abiraterone. Following discontinuation of abiraterone, creatine kinase concentrations decreased gradually throughout the duration of the hospitalization.<\/jats:p>","DOI":"10.1177\/1078155215620921","type":"journal-article","created":{"date-parts":[[2015,12,4]],"date-time":"2015-12-04T20:18:46Z","timestamp":1449260326000},"page":"148-151","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["Abiraterone-induced rhabdomyolysis: A case report"],"prefix":"10.1177","volume":"23","author":[{"given":"Donald C","family":"Moore","sequence":"first","affiliation":[{"name":"Southeast Missouri Hospital, Cape Girardeau, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Moore","sequence":"additional","affiliation":[{"name":"Southeast Missouri Hospital, Cape Girardeau, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,7,9]]},"reference":[{"key":"bibr1-1078155215620921","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2016"},{"key":"bibr2-1078155215620921","unstructured":"Product Information.\n                      Zytiga\n                      \u00ae\n                      oral tablets, abiraterone acetate oral tablets\n                      . Horsham, PA: Janssen Biotech Inc. (per FDA), 2014."},{"key":"bibr3-1078155215620921","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"bibr4-1078155215620921","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209096"},{"key":"bibr5-1078155215620921","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr6-1078155215620921","unstructured":"Product Information.\n                      Crestor\u00ae oral tablets, rosuvastatin calcium oral tablets\n                      . Wilmington, DE: AstraZeneca Pharmaceuticals LP (per FDA), 2013."},{"key":"bibr7-1078155215620921","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.21.2585"},{"key":"bibr8-1078155215620921","unstructured":"Rosuvastatin. In:\n                      Facts & Comparisons\n                      . St. Louis, MO: Wolters Kluwer Health. http:\/\/online.factsandcomparisons.com\/MonoDisp.aspx?monoID=fandc-hcp12420&quick=289212%7c5&search=289212%7c5&isstemmed=True&NDCmapping=-1&fromTop=true#firstMatch (accessed 25 October 2015)."},{"key":"bibr9-1078155215620921","unstructured":"Product Information: PredniSONE oral tablets solution, prednisone oral tablets solution. Roxane Laboratories, Inc., Columbus, OH, 2012."},{"key":"bibr10-1078155215620921","doi-asserted-by":"crossref","unstructured":"Beckett RD, Rodeffer KM and Snodgrass R. Abiraterone for the treatment of metastatic castrate-resistant prostate cancer.\n                      Ann Pharmacother\n                      2012; 46: 1016\u20131024.","DOI":"10.1345\/aph.1Q758"},{"key":"bibr11-1078155215620921","unstructured":"Mohler JL, Armstrong AJ, Bahnson RR, et al. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: prostate cancer. www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf (accessed 20 July 2015)."},{"key":"bibr12-1078155215620921","unstructured":"SEER Cancer Statistics Fact Sheets: Prostate Cancer. National Cancer Institute. Bethesda, MD. http:\/\/seer.cancer.gov\/statfacts\/html\/prost.html (accessed 20 July 2015)."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215620921","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155215620921","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215620921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:16:34Z","timestamp":1777688194000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155215620921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,9]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1177\/1078155215620921"],"URL":"https:\/\/doi.org\/10.1177\/1078155215620921","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,9]]}}}